MRT-048
/ Monte Rosa Therap, Cancer Research UK
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 07, 2021
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
(GlobeNewswire)
- "Discovered potent and highly selective GSPT1-directed molecular glue degraders, including the prototypical molecular glue degrader MRT-048, differentially induce cell death in Myc-driven cells versus non-Myc expressing control cells; Demonstrated GSPT1 degradation leads to anti-tumor activity in vivo in Myc-driven, biomarker-positive breast cancer models"
Preclinical • Breast Cancer • Oncology
1 to 1
Of
1
Go to page
1